Our Pricing

Get 10% off Your First Online Doctor Consultation

Published on: June 03, 2026

Looking for an online doctor consultation discount UK weight loss service? At Cured Pharmacy, new patients receive 10% off their first consultation for prescription weight loss treatments including Mounjaro, Wegovy, Saxenda, and Orlistat. Our UK-registered prescribers complete assessments in under 3 minutes, with transparent upfront pricing and discreet next-day delivery across the UK.

How the Online Doctor Consultation Discount Works for Weight Loss Treatments

Your discount applies automatically to the consultation fee when you complete your first clinical assessment at Cured Pharmacy. Our UK-registered prescribers review your medical history, current medications, and weight loss goals to determine the most appropriate treatment option from our range of MHRA-licensed medications [1].

The consultation process takes under 3 minutes and covers essential safety checks including BMI calculation, contraindications screening, and assessment of previous weight management attempts. All prescription weight loss medications in the UK require clinical approval from a registered prescriber before dispensing, ensuring patient safety and treatment suitability [2].

Once approved, you'll see transparent pricing for your prescribed medication before completing your order. Treatments are dispatched from our GPhC-registered pharmacy (9012511) in discreet packaging, typically arriving within 24 hours across mainland UK.

Prescription Weight Loss Treatments Available with Your Discounted Consultation

Cured Pharmacy offers the full spectrum of MHRA-licensed weight loss medications, each working through different mechanisms to support sustainable weight management. GLP-1 receptor agonists like Mounjaro, Wegovy, and Saxenda work by mimicking natural hormones that regulate appetite and blood sugar, whilst lipase inhibitors like Orlistat reduce dietary fat absorption [3].

Mounjaro contains tirzepatide, the first dual GIP/GLP-1 receptor agonist licensed in the UK, offering enhanced efficacy compared to single-pathway treatments. In the SURPASS-3 trial, patients achieved an average 22.5% body weight reduction over 72 weeks on the highest dose [1]. Wegovy and Saxenda contain semaglutide and liraglutide respectively, both proven GLP-1 treatments with robust clinical evidence.

For patients seeking non-injectable options, Orlistat and its branded versions Xenical and Alli work by blocking approximately 30% of dietary fat absorption. Mysimba combines naltrexone and bupropion to target appetite control through central nervous system pathways, offering an alternative mechanism for patients unsuitable for GLP-1 treatments [4].

Choosing Between Injectable and Oral Weight Loss Medications

Injectable GLP-1 treatments typically demonstrate greater weight loss outcomes in clinical trials but require weekly or daily self-administration. Oral medications like Orlistat and Mysimba may suit patients uncomfortable with injections, though efficacy profiles differ. Your UK prescriber will discuss these options during your discounted consultation, considering your medical history, lifestyle preferences, and weight loss goals to recommend the most appropriate treatment pathway.

Mounjaro: The Most Effective Weight Loss Treatment Available in the UK

Mounjaro (tirzepatide) represents the latest advancement in prescription weight loss medication, licensed by the MHRA in 2023. As a dual GIP/GLP-1 receptor agonist, it activates two complementary hormone pathways that regulate appetite, glucose metabolism, and energy expenditure — a mechanism unique among current UK-licensed treatments [1].

Clinical trial data demonstrates superior efficacy compared to earlier GLP-1 medications. The SURMOUNT-1 trial showed patients on tirzepatide 15mg achieved up to 22.5% body weight reduction over 72 weeks, compared to 15.8% with semaglutide 2.4mg in the STEP-1 trial [1][2]. These outcomes represent the highest weight loss percentages recorded in obesity pharmacotherapy trials to date.

Mounjaro is administered as a once-weekly subcutaneous injection using the convenient KwikPen device. Dosing begins at 2.5mg weekly for four weeks, then escalates gradually to minimise gastrointestinal side effects. Maintenance doses range from 5mg to 15mg weekly depending on individual response and tolerability, as determined by your prescriber during follow-up assessments [3].

Wegovy and Saxenda: Proven GLP-1 Weight Loss Injections

Wegovy contains semaglutide 2.4mg, a once-weekly GLP-1 receptor agonist with extensive clinical validation. The STEP trial programme demonstrated average weight loss of 15.8% over 68 weeks, with 86.4% of participants achieving at least 5% weight reduction — the threshold NICE considers clinically meaningful [2].

Saxenda uses liraglutide 3mg administered daily, making it suitable for patients who prefer more frequent dosing or require faster dose adjustments. Clinical trials showed average weight loss of 8% over 56 weeks, with particularly strong evidence for weight maintenance when combined with lifestyle modifications [5]. The daily injection schedule allows more granular dose titration compared to weekly alternatives.

Both medications work by slowing gastric emptying, reducing appetite, and enhancing satiety signals to the brain. Common side effects include nausea, diarrhoea, and constipation, typically most pronounced during dose escalation phases. These effects generally diminish within 4-8 weeks as the body adapts to treatment [3].

Comparing Weekly vs Daily GLP-1 Injections

Weekly injections like Mounjaro and Wegovy offer convenience and better adherence rates in clinical practice, whilst daily Saxenda injections provide more frequent dosing flexibility. Your prescriber will consider your lifestyle, previous medication adherence patterns, and personal preferences when recommending between these options during your consultation.

Orlistat: Non-Injectable Weight Loss Treatment Option

Orlistat works through a completely different mechanism than GLP-1 medications, making it suitable for patients who cannot tolerate or prefer to avoid injections. As a gastrointestinal lipase inhibitor, it blocks approximately 30% of dietary fat from being absorbed, instead passing it through the digestive system [4].

Available in 120mg prescription strength (Orlistat, Xenical) and 60mg over-the-counter strength (Alli, Orlos), the medication requires three-times-daily dosing with meals containing fat. Clinical trials demonstrate average weight loss of 5-10% over 12 months when combined with a reduced-calorie diet, making it particularly effective for patients committed to dietary modifications [6].

The main side effects relate to unabsorbed fat in the digestive tract, including oily stools, flatulence, and urgent bowel movements — effects that diminish significantly when patients follow a lower-fat diet (typically under 30% of calories from fat). Orlistat also reduces absorption of fat-soluble vitamins, so patients should take a daily multivitamin at least 2 hours before or after their Orlistat dose [4].

What to Expect During Your Online Doctor Consultation for Weight Loss

The consultation begins with a comprehensive medical questionnaire covering your weight history, previous weight loss attempts, current medications, and relevant health conditions. Our UK prescribers pay particular attention to contraindications for specific treatments — for example, personal or family history of medullary thyroid carcinoma contraindicates GLP-1 medications, whilst uncontrolled hypertension may affect Mysimba suitability [3][7].

You'll provide your current weight, height, and target weight goals, allowing the prescriber to calculate your BMI and assess treatment eligibility. NICE guidelines recommend prescription weight loss medications for patients with BMI ≥30 kg/m², or ≥27 kg/m² with weight-related comorbidities such as type 2 diabetes, hypertension, or sleep apnoea [8].

After reviewing your assessment, the prescriber approves the most appropriate treatment and starting dose. You'll then see transparent pricing before completing your order — there are no hidden consultation fees or surprise charges. Our superintendent pharmacist Tarun Kumar (GPhC 2233073) and his team dispense your medication from our GPhC-registered facility, with discreet packaging and tracked delivery as standard.

Follow-Up Support and Ongoing Prescriptions

Weight loss medications require ongoing monitoring to assess efficacy, tolerability, and dose adjustments. After your initial prescription, you'll complete brief follow-up consultations (typically monthly for GLP-1 treatments) to review progress and determine whether dose escalation is appropriate. These follow-up assessments ensure you receive optimal therapeutic benefit whilst minimising side effects throughout your weight loss journey.

Scientific References

1. Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., et al. (2022). Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine, 387(3), 205–216. https://doi.org/10.1056/NEJMoa2206038 [accessed 13 August 2026]
2. Wilding, J. P. H., Batterham, R. L., Calanna, S., et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine, 384(11), 989–1002. https://doi.org/10.1056/NEJMoa2032183 [accessed 13 August 2026]
3. Medicines and Healthcare products Regulatory Agency. (2023). Summary of Product Characteristics: Mounjaro 2.5 mg solution for injection in pre-filled pen. GOV.UK. https://www.gov.uk/guidance/regulatory-approval-of-mounjaro-tirzepatide [accessed 13 August 2026]
4. Torgerson, J. S., Hauptman, J., Boldrin, M. N., & Sjöström, L. (2004). XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. Diabetes Care, 27(1), 155–161. https://doi.org/10.2337/diacare.27.1.155 [accessed 13 August 2026]
5. Pi-Sunyer, X., Astrup, A., Fujioka, K., et al. (2015). A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management. New England Journal of Medicine, 373(1), 11–22. https://doi.org/10.1056/NEJMoa1411892 [accessed 13 August 2026]
6. Sjöström, L., Rissanen, A., Andersen, T., et al. (1998). Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients. The Lancet, 352(9123), 167–172. https://doi.org/10.1016/S0140-6736(97)11509-4 [accessed 13 August 2026]
7. Greenway, F. L., Fujioka, K., Plodkowski, R. A., et al. (2010). Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. The Lancet, 376(9741), 595–605. https://doi.org/10.1016/S0140-6736(10)60888-4 [accessed 13 August 2026]
8. National Institute for Health and Care Excellence. (2023). Obesity: identification, assessment and management (CG189). NICE. https://www.nice.org.uk/guidance/cg189 [accessed 13 August 2026]

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Always consult a qualified healthcare professional before starting any new medication. Weight loss results vary between individuals and depend on multiple factors including adherence to treatment, dietary modifications, and physical activity levels.